Radiation Therapy and Gadolinium Texaphyrin in Treating Patients With Supratentorial Glioblastoma Multiforme

National Cancer Institute (NCI)12 enrolled

Overview

Phase I trial to study the effectiveness of radiation therapy and gadolinium texaphyrin in treating patients who have supratentorial glioblastoma multiforme. Radiation therapy uses high-energy x-rays to damage tumor cells. Drugs such as gadolinium texaphyrin may make the tumor cells more sensitive to radiation therapy.

PRIMARY OBJECTIVES: I. Determine the frequency and grade of toxicity of gadolinium texaphyrin as a radiosensitizer at two dose levels in patients with supratentorial glioblastoma multiforme undergoing stereotactic radiosurgery. II. Compare the tumor, normal brain, and plasma concentrations of this drug regimen to 1.5 and 8 Tesla MRI images in this patient population. III. Determine if the 8 Tesla images provide more data than the 1.5 Tesla images in terms of the radiosensitizing drug distribution in the tumor in these patients. OUTLINE: This is a dose escalation study. Within 5 weeks following surgery, patients receive daily external beam radiotherapy five days a week for 5 weeks. Within 2 weeks following completion of radiotherapy, patients receive gadolinium texaphyrin IV over 2 hours followed 3 hours later by stereotactic radiosurgery. Patients undergoing surgical debulking of tumor prior to external beam radiotherapy receive gadolinium texaphyrin IV over 2 hours, 3 hours prior to surgery in addition to the dose prior to stereotactic radiosurgery. Cohorts of 3-6 patients receive escalating doses of gadolinium texaphyrin until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose limiting toxicity. Patients are followed monthly for 3 months, and then every 3 months for 5 years or until death. PROJECTED ACCRUAL: Approximately 12-18 patients will be accrued for this study within 12-18 months.

Study Type

INTERVENTIONAL

Allocation

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Adult Giant Cell Glioblastoma Adult Glioblastoma Adult Gliosarcoma

Interventions

conventional surgeryPROCEDURE

3-dimensional conformal radiation therapyRADIATION

stereotactic radiosurgeryRADIATION

motexafin gadoliniumDRUG

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Histologically confirmed supratentorial glioblastoma multiforme by stereotactic biopsy, open biopsy, or resection * Maximum diameter of the tumor mass must be no greater than 4 cm in any dimension, including following debulking surgery * Tumor must be at least 1.0 cm from the optic chiasm and brainstem * No oligodendrogliomas, meningiomas, or grade I, II, or III astrocytomas * No infratentorial tumors * No multifocal glioblastoma multiforme * Tumor enhances on MRI * Must have visible tumor on postoperative MRI following surgical resection * Performance status - Karnofsky 60-100% * At least 3 months * Hemoglobin at least 10.0 g/dL * Absolute neutrophil count at least 1,500/mm\^3 * Platelet count at least 100,000/mm\^3 * Bilirubin no greater than 1.5 mg/dL * SGPT no greater than 60 U/L * Creatinine no greater than 1.3 mg/dL * Blood urea nitrogen no greater than 24 mg/dL * Neurological function status 0-3 * No evidence of neuropathy * No glucose-6-phosphate dehydrogenase deficiency * No known history of porphyria * History of prior malignancies allowed * HIV positive status allowed * No medical contraindication to MRI imaging (i.e., pacemaker, aneurysm clip, or nonsecure metal fragment close to a critical structure) * Not pregnant or nursing * Negative pregnancy test * Fertile patients must use effective contraception prior to and during study * At least 6 weeks since prior chemotherapy * Concurrent steroids allowed * No prior radiotherapy to the brain or upper neck * No greater than 5 weeks since prior surgery and recovered

Locations (1)

Arthur G. James Cancer Hospital and Solove Research Institute at Ohio State University Medical Center

Columbus, Ohio, United States

Outcomes

Primary Outcomes

Maximum-tolerated dose (MTD) based on the incidence of dose-limiting toxicity (DLT), as assessed by the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 2.0

Time frame: At the time of stereotactic radiosurgery

Secondary Outcomes

Concentration of gadolinium in tumor, normal brain, and plasma by plasma-atomic emission spectroscopy and liquid chromatography with mass spectrometry

Time frame: At baseline, at 48 hours, and at 2 weeks post-surgery

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.